2,4, (4,6) PYRIMIDINE DERIVATIVES
The present invention concerns the compounds of formula (I), the N-oxide fonns, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z1 and Z2 represent NH; Y represents -C3_9alkyl-, -C3_9alkenyl-, -C1 -salkyl-NR 6- C1 -salkyl-, -C1_5alkyl-NR 7- CO-...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Patent |
Language | English |
Published |
11.04.2019
|
Online Access | Get full text |
Cover
Loading…
Abstract | The present invention concerns the compounds of formula (I), the N-oxide fonns, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z1 and Z2 represent NH; Y represents -C3_9alkyl-, -C3_9alkenyl-, -C1 -salkyl-NR 6- C1 -salkyl-, -C1_5alkyl-NR 7- CO-C1 _ 5alkyl-, -C1-6alkyl-CO-NH-, -C1-6alkyl-NH-CO-, -C1 _2a lkyl-CO-H et10-CO-, -C1 _ 3alkyl-NH-CO-H et3-, -Het4-C1_3alkyl-CO-NH-C 1 _3alkyl-, -C1-2alkyl-NH-CO-L1- NH-, -NH-CO-L2-NH-, -C1-2 alkyl-CO-NH-L 3-CO-, -C1_2alkyl-NH-CO-L 1 -NH-CO- C1_3alkyl-, -C1 -2alkyl-CO-NH-L 3-CO-NH-C 1_3alkyl-, -C 1-2alkyl-NR 11 -CH2- CO-NH-C1_3alkyl-, Het5-CO-C1 -2alkyl-, -C1 _5alkyl-CO-NH-C 1 _3alkyl-CO-NH-, -C1 _5alkyl-NR 1 3-CO-C1 _3alkyl-NH-, -C1 _3alkyl-NH-CO-Het27- CO-, or -C1 _3alkyl-CO- Het28-CO-NH-?, X1 represents a direct bond, 0, -O-C1 _2alkyl-, -CO-C1 _2alkyl-, -NR16-C1 _2alkyl-, -CO- NR17-, Het23- C1 _2alkyl- or C1-2alkyl; X2 represents a direct bond, 0, -O-C1 _2alkyl-, -CO-C1 _2alkyl-, -NR18 -C1 _2alkyl-, -CO- NR19-, Het24-C1-2alkyl- or C1-2alkyl; R1 and R5 each independently represent hydrogen, halo, C1_6alkyloxy- or C1 _6alkyloxy- substituted with Het1 or C1-4alkyloxy-; R2 and R4 each independently represent hydrogen or halo; R3 represents hydrogen or cyano; R6, R7, R1 3, R17 and R19 represent hydrogen; R11 represents hydrogen or C14 alkyl; R16 and R18 represent hydrogen, C14 a lkyl or Het17 -C14 alkyl-; L1 , L2 and L3 each independently represents C1 _8al kyl optionally substituted with one or where possible two or more substituents selected from phenyl, methylsulfide, cyano, polyhaloC1-4alkyl-phenyl-, C1-4alkyloxy, pyridinyl, mono- or di(C14 a lkyl)- amino- or C3_6cycloalkyl; Het1 , Het 2, Het 17 each independently represent morpholinyl, oxazolyl, isoxazolyl, or piperazinyl; Het3, Het 4, Het5 each independently represent morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl; Het 1 0 represents piperazinyl, piperidinyl, pyrrolidinyl or azetidinyl; Het22 represents morpholinyl, oxazolyl, isoxazolyl or piperazinyl wherein said Het22 is optionally substituted with C14 a lkyl; Het23 and He t24 each independently represent a heterocycle selected from pyrrolidinyl, piperazinyl or piperidinyl wherein said Het23 or Het24 are optionally substituted with Het 22-carbonyl; Het 27 and Het28 each independently represent a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl. |
---|---|
AbstractList | The present invention concerns the compounds of formula (I), the N-oxide fonns, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z1 and Z2 represent NH; Y represents -C3_9alkyl-, -C3_9alkenyl-, -C1 -salkyl-NR 6- C1 -salkyl-, -C1_5alkyl-NR 7- CO-C1 _ 5alkyl-, -C1-6alkyl-CO-NH-, -C1-6alkyl-NH-CO-, -C1 _2a lkyl-CO-H et10-CO-, -C1 _ 3alkyl-NH-CO-H et3-, -Het4-C1_3alkyl-CO-NH-C 1 _3alkyl-, -C1-2alkyl-NH-CO-L1- NH-, -NH-CO-L2-NH-, -C1-2 alkyl-CO-NH-L 3-CO-, -C1_2alkyl-NH-CO-L 1 -NH-CO- C1_3alkyl-, -C1 -2alkyl-CO-NH-L 3-CO-NH-C 1_3alkyl-, -C 1-2alkyl-NR 11 -CH2- CO-NH-C1_3alkyl-, Het5-CO-C1 -2alkyl-, -C1 _5alkyl-CO-NH-C 1 _3alkyl-CO-NH-, -C1 _5alkyl-NR 1 3-CO-C1 _3alkyl-NH-, -C1 _3alkyl-NH-CO-Het27- CO-, or -C1 _3alkyl-CO- Het28-CO-NH-?, X1 represents a direct bond, 0, -O-C1 _2alkyl-, -CO-C1 _2alkyl-, -NR16-C1 _2alkyl-, -CO- NR17-, Het23- C1 _2alkyl- or C1-2alkyl; X2 represents a direct bond, 0, -O-C1 _2alkyl-, -CO-C1 _2alkyl-, -NR18 -C1 _2alkyl-, -CO- NR19-, Het24-C1-2alkyl- or C1-2alkyl; R1 and R5 each independently represent hydrogen, halo, C1_6alkyloxy- or C1 _6alkyloxy- substituted with Het1 or C1-4alkyloxy-; R2 and R4 each independently represent hydrogen or halo; R3 represents hydrogen or cyano; R6, R7, R1 3, R17 and R19 represent hydrogen; R11 represents hydrogen or C14 alkyl; R16 and R18 represent hydrogen, C14 a lkyl or Het17 -C14 alkyl-; L1 , L2 and L3 each independently represents C1 _8al kyl optionally substituted with one or where possible two or more substituents selected from phenyl, methylsulfide, cyano, polyhaloC1-4alkyl-phenyl-, C1-4alkyloxy, pyridinyl, mono- or di(C14 a lkyl)- amino- or C3_6cycloalkyl; Het1 , Het 2, Het 17 each independently represent morpholinyl, oxazolyl, isoxazolyl, or piperazinyl; Het3, Het 4, Het5 each independently represent morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl; Het 1 0 represents piperazinyl, piperidinyl, pyrrolidinyl or azetidinyl; Het22 represents morpholinyl, oxazolyl, isoxazolyl or piperazinyl wherein said Het22 is optionally substituted with C14 a lkyl; Het23 and He t24 each independently represent a heterocycle selected from pyrrolidinyl, piperazinyl or piperidinyl wherein said Het23 or Het24 are optionally substituted with Het 22-carbonyl; Het 27 and Het28 each independently represent a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl. |
Author | EMBRECHTS, WERNER CONSTANT JOHAN VAN EMELEN, KRISTOF VAN BRANDT, SVEN FRANCISCUS ANNA ROMBOUTS, FREDERIK JAN RITA FREYNE, EDDY JEAN EDGARD WILLEMS, MARC |
Author_xml | – fullname: ROMBOUTS, FREDERIK JAN RITA – fullname: FREYNE, EDDY JEAN EDGARD – fullname: WILLEMS, MARC – fullname: VAN BRANDT, SVEN FRANCISCUS ANNA – fullname: EMBRECHTS, WERNER CONSTANT JOHAN – fullname: VAN EMELEN, KRISTOF |
BookMark | eNrjYmDJy89L5WRQNNIx0VHQMNEx01QIiAzy9PV08fRzVXBxDfIMcwzxDHMN5mFgTUvMKU7lhdLcDHJuriHOHrqpBfnxqcUFicmpeakl8b6RhmaWJiaGjsYEFQAAySciAQ |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
ExternalDocumentID | MY169441A |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_MY169441A3 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 14:55:37 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_MY169441A3 |
Notes | Application Number: MY2005PI05703 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190411&DB=EPODOC&CC=MY&NR=169441A |
ParticipantIDs | epo_espacenet_MY169441A |
PublicationCentury | 2000 |
PublicationDate | 20190411 |
PublicationDateYYYYMMDD | 2019-04-11 |
PublicationDate_xml | – month: 04 year: 2019 text: 20190411 day: 11 |
PublicationDecade | 2010 |
PublicationYear | 2019 |
RelatedCompanies | JANSSEN PHARMACEUTICA, N.V |
RelatedCompanies_xml | – name: JANSSEN PHARMACEUTICA, N.V |
Score | 3.2052064 |
Snippet | The present invention concerns the compounds of formula (I), the N-oxide fonns, the pharmaceutically acceptable addition salts and the stereochemically... |
SourceID | epo |
SourceType | Open Access Repository |
Title | 2,4, (4,6) PYRIMIDINE DERIVATIVES |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190411&DB=EPODOC&locale=&CC=MY&NR=169441A |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3dS8MwED_mFPVN5_fHqCBFoWVLe636UGTrB5vQrsxa1qexxkZ8mcNV_Pe9lE592VtI4JIc_O6XS-4uANdo5MJkBtfJ_RE6CmR6bgqms9mMd5l4lVnMMtoisgcv-DSxJg14W-XCVHVCv6viiIQoTngvK3u9-LvE8qrYymUnf6euj8cgcTy19o6J3ZCw6_UdPx55I1d1XSfM1GjsMPuBiL-3AZvyDC2L7PtpX6akLP7zSbAHWzGJmpf70CjmLdhxV9-utWA7rF-7qVkDb3kAV4aGmnKDmn2rxNmYLI43jHzFIzcs7SXD1H8-hHbgJ-5Ap7mmv7uahlm9JvMImuTqFyegsNzkeCcMK-eIJlE_mgUWhaypbnX5vXUKx2uEnK0dOYddqRj5AsLYBTTLz6_ikoi0zNuVEn4AZwpzRA |
link.rule.ids | 230,309,786,891,25594,76904 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1LT4NAEJ7Uaqw3re9HxcQQTSB2YaF6IKblEdBCSaWknEjBxXipjcX4950lVL30ttlNZncnmfny7TwW4JoqWaESJZeR_hQyLSiRM7UgMpnN8i4pXnkVM8-2CHR3Qp-m2rQBb6tamKpP6HfVHBEtKkd7Lyt_vfh7xLKq3MrlXfaOUx-PTmRYYs2OEd0o2q41MOxwZI1M0TQNPxGDsUH0BwT-_gZs9pAP8ib7djzgJSmL_3ji7MJWiKLm5R402LwNLXP17Vobtv062o3D2vCW-3ClSFQSbqik3wphMkaPY3mBLVhIw-J-5MX2ywF0HDsyXRn3Sn9vlfpJfSb1EJpI9dkxCCRTc9orFC3LKVUR-qnKKGO8p7rWze-1EzhaI-R07coltNzIH6ZDL3g-gx2uJB4NIeQcmuXnF7tAUC2zTqWQH_Bhdi8 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=2%2C4%2C+%284%2C6%29+PYRIMIDINE+DERIVATIVES&rft.inventor=ROMBOUTS%2C+FREDERIK+JAN+RITA&rft.inventor=FREYNE%2C+EDDY+JEAN+EDGARD&rft.inventor=WILLEMS%2C+MARC&rft.inventor=VAN+BRANDT%2C+SVEN+FRANCISCUS+ANNA&rft.inventor=EMBRECHTS%2C+WERNER+CONSTANT+JOHAN&rft.inventor=VAN+EMELEN%2C+KRISTOF&rft.date=2019-04-11&rft.externalDBID=A&rft.externalDocID=MY169441A |